Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Mar 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study aimed to investigate the risk of infection with ibrutinib treatment in B-cell malignancies such as lymphoma. 

This study concluded that ibrutinib was associated with a higher risk of infections in these patients.

Some background

B-cell malignancies such as non-Hodgkin lymphoma (NHL) lead to an increased risk of infection. This is due to immune defects associated with cancer. Ibrutinib (Imbruvica) is a targeted therapy used in the treatment of NHL. It was unknown what the risk of infection is in patients with B-cell malignancies treated with ibrutinib

Methods & findings

This study analyzed results from 7 studies that involved a total of 2167 patients. These studies compared ibrutinib to other agents for B-cell malignancy treatment. Patients were treated for a duration of 9.4 months to 38.7 months.  

Ibrutinib was associated with an increased risk of infection in patients with B-cell malignancies (46%) compared to other treatments (37%). Ibrutinib was associated with a 34% higher risk of infections of any severity and a 35% higher risk of serious and life-threatening infections.

There was no significant difference in the risk of pneumonia and upper respiratory tract infection between groups.

The bottom line

This study concluded that ibrutinib was associated with a higher risk of infections in patients with B-cell malignancies. 

The fine print

The studies analyzed had different protocols. Patients received ibrutinib as frontline therapy or for relapsed/unresponsive disease. The risk of infection may be different between these categories of patients. Further studies are needed.  

Published By :

Clinical lymphoma, myeloma & leukemia

Date :

Feb 01, 2020

Original Title :

Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

click here to get personalized updates